Brazil details drug approval process and biosafety lab standards

In Brazil, developing a new medication or vaccine typically requires about ten years. The pathway starts with basic research to identify a target molecule, proceeds through pre‑clinical testing on animals, and then three phases of clinical trials with human volunteers. After each phase, the National Health Surveillance Agency (Anvisa) reviews the data, a process that can take six months to two years. Successful trials lead to registration, potential inclusion in the public health system (SUS) after cost‑effectiveness assessment by Conitec, and post‑marketing pharmacovigilance. The article notes that the Ministry of Health recently suspended the use of Butantan’s dengue vaccine following reports of serious adverse events.

Brazil’s biosafety framework classifies laboratories into four levels (NB1‑NB4) based on the risk of the biological agents handled. The Ministry of Health sets the criteria, requiring progressively stricter containment, personal protective equipment, ventilation, and decontamination measures for higher‑risk levels. NB4 facilities, such as the planned Orion laboratory by the National Center for Research in Energy and Materials, employ maximum‑containment protocols to protect personnel, the public, and the environment.